Berberine improves glucose and lipid metabolism in HepG2 cells through AMPK1 activation
"Your firm became aware of the event on June 20, 2024, and FDA received the MDR, 1220908202500947, for the corresponding incident on March 10, 2025, which is beyond the 30calendar day timeframe." FDA issued warning letters to three drug manufacturers, including the Canadian over-the-counter drugmaker Sante Manufacturing, for failing to adhere to CGMP requirements
Discussion In this large population-based study of individuals with NAFLD and type 2 diabetes, three major CVEs and mortality rate were compared between patients treated with and without GLP-1RAs treatment
Months 3 to 6: This is typically the period of maximum weight loss velocity
Research suggests that people with epilepsy are 28% more likely to have obesity than the general population, partly driven by anti-epileptic drugs (AEDs) that cause weight gain as a side effect